Luraprex40 mg

Luraprex 40 mg is an atypical (second-generation) antipsychotic with the following evidence-based indications:

• Schizophrenia (FDA-approved): Treatment of schizophrenia in adults and adolescents aged 13-17 years.
• Bipolar Depression (FDA-approved): Treatment of major depressive episodes associated with bipolar I disorder in adults and pediatric patients aged 10-17 years, as monotherapy or as adjunctive therapy with lithium or valproate.

Luraprex 40 mg is not approved for the treatment of dementia-related psychosis in elderly patients (see Precautions and Warnings for boxed warning).

Off-label use of Luraprex 40 mg for other psychiatric conditions has been reported in limited clinical experience but is not well established and should only be considered under specialist psychiatric supervision.

Each film-coated tablet contains Luraprex 40 mg equivalent to lurasidone base, commonly available in strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg (available strengths may vary by market/manufacturer).

Luraprex 40 mg is an atypical antipsychotic agent belonging to the benzisothiazole derivative class. It is used in the management of schizophrenia and depressive episodes associated with bipolar I disorder. Luraprex 40 mg works primarily by modulating dopamine and serotonin receptor activity in the brain, and is generally associated with a lower risk of weight gain and metabolic disturbance compared with some other atypical antipsychotics, although these effects can still occur.

Atypical (second-generation) antipsychotic; benzisothiazole derivative.

Luraprex 40 mg exerts its therapeutic effect through antagonism of dopamine D2 and serotonin 5-HT2A receptors, along with high-affinity antagonism at serotonin 5-HT7 receptors and partial agonism at serotonin 5-HT1A receptors. This combined receptor profile is thought to underlie its efficacy in both positive/negative symptoms of schizophrenia and depressive symptoms of bipolar I disorder. Luraprex 40 mg has minimal affinity for histamine H1 and muscarinic M1 receptors, which contributes to a comparatively lower propensity for sedation, weight gain, and anticholinergic side effects relative to some other atypical antipsychotics.

Luraprex 40 mg is metabolized primarily via the hepatic CYP3A4 enzyme pathway, and its absorption is significantly increased (up to 3-fold) when taken with food (at least 350 calories), so it must be administered with a meal.

Luraprex 40 mg is primarily metabolized by CYP3A4, and its blood levels are significantly affected by drugs that inhibit or induce this enzyme:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir): contraindicated in combination with Luraprex 40 mg due to markedly increased drug exposure and risk of toxicity.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): contraindicated in combination with Luraprex 40 mg due to markedly reduced drug levels and loss of efficacy.
• Moderate CYP3A4 inhibitors (e.g., diltiazem): concurrent use requires a reduced dose of Luraprex 40 mg.
• Moderate CYP3A4 inducers: may require a dose increase of Luraprex 40 mg, with dose reduction after the inducer is discontinued.
• CNS depressants (alcohol, benzodiazepines, opioids): additive sedation risk when combined with Luraprex 40 mg.
• Antihypertensive agents: increased risk of orthostatic hypotension when used with Luraprex 40 mg.
• Other centrally-acting drugs/dopaminergic agents: may have additive or antagonistic effects with Luraprex 40 mg; use with caution.

Common side effects associated with Luraprex 40 mg include:

• Akathisia (restlessness)
• Somnolence (drowsiness)
• Nausea
• Parkinsonism (tremor, rigidity, bradykinesia)
• Agitation
• Insomnia
• Dizziness
• Vomiting

Less common but serious effects include neuroleptic malignant syndrome, tardive dyskinesia, orthostatic hypotension/syncope, metabolic changes (hyperglycemia, dyslipidemia, weight gain - see Precautions and Warnings), and leukopenia/neutropenia. Seek prompt medical attention for severe muscle stiffness, high fever, confusion, irregular heartbeat, or fainting while taking Luraprex 40 mg.

Pregnancy: Data on the use of Luraprex 40 mg in pregnancy are limited. Antipsychotic use, including Luraprex 40 mg, during the third trimester of pregnancy has been associated with a risk of extrapyramidal and/or withdrawal symptoms in newborns, such as agitation, abnormal muscle tone, tremor, and feeding difficulty. Luraprex 40 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under close physician supervision. Enrollment in a pregnancy exposure registry (where available) should be discussed with the physician.

Lactation: It is not fully established whether Luraprex 40 mg passes into human breast milk, but antipsychotics are generally assumed to be excreted in breast milk to some degree. Breastfeeding while using Luraprex 40 mg should only be undertaken after consulting a physician, weighing the benefits of breastfeeding against the possible risk of infant exposure and the mother's clinical need for the medicine.

Boxed Warning: Elderly patients with dementia-related psychosis treated with antipsychotic drugs, including Luraprex 40 mg, are at increased risk of death compared with placebo. Luraprex 40 mg is not approved for the treatment of dementia-related psychosis.

Other Warnings

• Neuroleptic Malignant Syndrome (NMS): a rare but potentially fatal syndrome (hyperthermia, muscle rigidity, altered consciousness, autonomic instability) can occur with Luraprex 40 mg; discontinue immediately if suspected.
• Tardive Dyskinesia: risk of potentially irreversible involuntary movements with prolonged use; use the lowest effective dose for the shortest duration necessary.
• Metabolic Changes: hyperglycemia, new-onset diabetes, dyslipidemia, and weight gain can occur with Luraprex 40 mg, although its overall metabolic profile is generally more favorable than some other atypical antipsychotics; monitor blood glucose, lipids, and weight periodically.
• Orthostatic Hypotension/Syncope: particularly at treatment initiation and dose escalation; use caution in patients with cardiovascular disease, cerebrovascular disease, or dehydration.
• Leukopenia, Neutropenia, and Agranulocytosis: monitor complete blood counts in patients with a history of low white blood cell count.
• Seizures: use cautiously in patients with a history of seizure disorder.
• Cognitive and Motor Impairment: Luraprex 40 mg may impair judgment, thinking, or motor skills; caution when driving or operating machinery.
• Body Temperature Dysregulation: use caution in conditions predisposing to elevated core body temperature (strenuous exercise, extreme heat, dehydration).
• Dietary Requirement: must be taken with food (at least 350 calories) for adequate absorption; missing this may reduce effectiveness.

Overdose with Luraprex 40 mg may present with somnolence, sedation, tachycardia, hypotension, and extrapyramidal symptoms. There is no specific antidote for Luraprex 40 mg overdose. In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. Management is supportive and symptomatic, and should be carried out under close medical supervision, including cardiovascular monitoring, in a hospital setting; do not attempt home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Use Luraprex 40 mg with caution in elderly patients, particularly those with dementia-related psychosis, due to the boxed warning of increased mortality risk (see Precautions and Warnings); this population may also be more susceptible to orthostatic hypotension and sedation.

Renal Impairment: Dose adjustment of Luraprex 40 mg is required in moderate to severe renal impairment (see Dosage and Administration).

Hepatic Impairment: Dose adjustment of Luraprex 40 mg is required in moderate to severe hepatic impairment (see Dosage and Administration).

Pediatric: Safety and efficacy of Luraprex 40 mg have been established for schizophrenia in adolescents 13-17 years and for bipolar depression in patients 10-17 years; safety and efficacy have not been established in children below these age ranges or for other indications.

Atypical antipsychotics; benzisothiazole derivatives.

Luraprex 40 mg is approved for use in:

• Schizophrenia in adolescents aged 13-17 years (dose range 40-80 mg/day).
• Depressive episodes associated with bipolar I disorder in pediatric patients aged 10-17 years (dose range 20-80 mg/day).

Safety and efficacy of Luraprex 40 mg have not been established in children below these age ranges or for other psychiatric indications. Use in pediatric patients should be supervised by a specialist experienced in pediatric psychiatric disorders, with periodic monitoring for metabolic, movement-related, and behavioral changes.